Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Less dead space waste
Disappointing GLP-1 Results in Alzheimers Trial: Underscores Promise (and Limits) of Single-Agent Approaches Key takeaways Two large Phase 3 trials (EVOKE and EVOKE+) of oral semaglutide (a GLP1 receptor agonist) in early Alzheimers disease showed no significant slowing of cognitive or functional decline vs
Blood sugar control: Clinical trials show that about 66% of patients taking semaglutide achieved significant blood sugar control (HbA1c below 7%) compared to a lower percentage in the placebo group, demonstrating its effectiveness in effectively managing blood sugar levels in people with type 2 diabetes
They also experienced slight decreases in body weight, fat mass, and hip circumference
These agents, known for their dual impact on both immune modulation and metabolic improvement, offer a unique therapeutic potential in managing immune-mediated inflammatory diseases ( 3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib ( Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)
Moreover, the concurrent use of biologics and AIT works synergistically to induce immune tolerance
US$ 21.09
US$ 22.22
US$ 21.61
US$ 29.43
US$ 21.00
US$ 28.52
US$ 25.66
